Literature DB >> 19346183

Cytotoxic activity of sanguinarine and dihydrosanguinarine in human promyelocytic leukemia HL-60 cells.

Jirí Vrba1, Petr Dolezel, Jaroslav Vicar, Jitka Ulrichová.   

Abstract

The benzo[c]phenanthridine alkaloid sanguinarine has been studied for its antiproliferative activity in many cell types. Almost nothing however, is known about the cytotoxic effects of dihydrosanguinarine, a metabolite of sanguinarine. We compared the cytotoxicity of sanguinarine and dihydrosanguinarine in human leukemia HL-60 cells. Sanguinarine produced a dose-dependent decline in cell viability with IC(50) (inhibitor concentration required for 50% inhibition of cell viability) of 0.9 microM as determined by MTT assay after 4h exposure. Dihydrosanguinarine showed much less cytotoxicity than sanguinarine: at the highest concentration tested (20 microM) and 24h exposure, dihydrosanguinarine decreased viability only to 52%. Cytotoxic effects of both alkaloids were accompanied by activation of the intrinsic apoptotic pathway since we observed the dissipation of mitochondrial membrane potential, induction of caspase-9 and -3 activities, the appearance of sub-G(1) DNA and loss of plasma membrane asymmetry. This aside, sanguinarine also increased the activity of caspase-8. As shown by flow cytometry using annexin V/propidium iodide staining, 0.5 microM sanguinarine induced apoptosis while 1-4 microM sanguinarine caused necrotic cell death. In contrast, dihydrosanguinarine at concentrations from 5 microM induced primarily necrosis, whereas apoptosis occurred at 10 microM and above. We conclude that both alkaloids may cause, depending on the alkaloid concentration, both necrosis and apoptosis of HL-60 cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346183     DOI: 10.1016/j.tiv.2009.01.016

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  9 in total

Review 1.  Natural isoquinoline alkaloids: binding aspects to functional proteins, serum albumins, hemoglobin, and lysozyme.

Authors:  Asma Yasmeen Khan; Gopinatha Suresh Kumar
Journal:  Biophys Rev       Date:  2015-11-16

2.  Sanguinarine impairs lysosomal function and induces ROS-dependent mitophagy and apoptosis in human hepatocellular carcinoma cells.

Authors:  Jingjing Wang; Qi Su; Qing Wu; Kun Chen; Asmat Ullah; Mohsin Ahmad Ghauri; Yanmin Zhang
Journal:  Arch Pharm Res       Date:  2021-11-09       Impact factor: 4.946

3.  Natural Protein Kinase Inhibitors, Staurosporine, and Chelerythrine Suppress Wheat Blast Disease Caused by Magnaporthe oryzae Triticum.

Authors:  Moutoshi Chakraborty; S M Fajle Rabby; Dipali Rani Gupta; Mahfuzur Rahman; Sanjoy Kumar Paul; Nur Uddin Mahmud; Abdullah Al Mahbub Rahat; Ljupcho Jankuloski; Tofazzal Islam
Journal:  Microorganisms       Date:  2022-06-09

4.  2-(2-Hy-droxy-phen-yl)-3,4-dihydro-iso-quinolin-1(2H)-one.

Authors:  Jian Yang; Yanni Ma; Meng Pan; Fangjun Cao; Le Zhou
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-09-30

5.  Dihydrosanguinarine Enhances Glucose Uptake in Mouse 3T3-L1 Cells.

Authors:  Yit-Lai Chow; Yuko Iwata; Fumihiko Sato
Journal:  ACS Omega       Date:  2017-10-19

6.  IGFBP-3 Is the Key Target of Sanguinarine in Promoting Apoptosis in Hepatocellular Carcinoma.

Authors:  Huiwen Wang; He Wang; Kai Li; Shijie Li; Bingyi Sun
Journal:  Cancer Manag Res       Date:  2020-02-11       Impact factor: 3.989

7.  Identification of a Novel Antibiotic from Myxobacterium Stigmatella Eracta WXNXJ-B and Evaluation of its Antitumor Effects I n - vitro.

Authors:  Dahong Wang; Jiangfeng Yuan; Wenyi Tao
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

Review 8.  Toxicological Effects of Berberine and Sanguinarine.

Authors:  Nitika Singh; Bechan Sharma
Journal:  Front Mol Biosci       Date:  2018-03-19

9.  Synthesis and Anticancer Activity Evaluation of Novel Phenanthridine Derivatives.

Authors:  Minghui Wan; Lei Zhang; Yiming Chen; Qiang Li; Wenli Fan; Qingxia Xue; Fang Yan; Weiguo Song
Journal:  Front Oncol       Date:  2019-04-16       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.